Haemonetics FY2025 EPS Estimate Reduced by Zacks Research

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research cut their FY2025 earnings estimates for shares of Haemonetics in a research report issued on Thursday, March 13th. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $4.54 per share for the year, down from their prior estimate of $4.56. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q4 2025 earnings at $1.21 EPS, Q1 2026 earnings at $1.11 EPS, Q2 2026 earnings at $1.22 EPS, Q3 2026 earnings at $1.34 EPS, Q4 2026 earnings at $1.34 EPS, FY2026 earnings at $5.00 EPS, Q1 2027 earnings at $1.37 EPS and FY2027 earnings at $5.73 EPS.

A number of other equities analysts have also recently weighed in on the stock. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target on the stock. Needham & Company LLC reduced their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday. Barrington Research reduced their price target on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, JMP Securities reduced their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $101.22.

Haemonetics Stock Performance

NYSE:HAE opened at $64.69 on Monday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm has a 50-day moving average of $68.08 and a two-hundred day moving average of $75.26. The stock has a market cap of $3.25 billion, a P/E ratio of 25.47, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics has a 1-year low of $58.80 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%.

Institutional Investors Weigh In On Haemonetics

Several institutional investors and hedge funds have recently bought and sold shares of HAE. Victory Capital Management Inc. raised its stake in Haemonetics by 0.6% during the third quarter. Victory Capital Management Inc. now owns 278,886 shares of the medical instruments supplier’s stock worth $22,417,000 after acquiring an additional 1,717 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Haemonetics by 29.5% in the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock valued at $88,433,000 after purchasing an additional 250,833 shares during the period. Segall Bryant & Hamill LLC increased its stake in shares of Haemonetics by 0.7% in the third quarter. Segall Bryant & Hamill LLC now owns 62,621 shares of the medical instruments supplier’s stock valued at $5,033,000 after purchasing an additional 407 shares during the period. Global Alpha Capital Management Ltd. acquired a new stake in shares of Haemonetics in the third quarter valued at approximately $806,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Haemonetics by 439.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 220,453 shares of the medical instruments supplier’s stock valued at $17,720,000 after purchasing an additional 179,621 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.